市場調査レポート

世界の多発性骨髄腫治療薬市場

Multiple Myeloma Therapeutics

発行 Global Industry Analysts, Inc. 商品コード 225235
出版日 ページ情報 英文 595 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

Back to Top
世界の多発性骨髄腫治療薬市場 Multiple Myeloma Therapeutics
出版日: 2011年10月01日 ページ情報: 英文 595 Pages
概要

当レポートでは、世界の多発性骨髄腫治療薬市場について分析し、米国、欧州におけるセグメント別市場動向、2009〜2017年の予測、市場に参入する企業のプロファイルなどをまとめ、概略下記の構成で取り上げております。

第1章 イントロダクション・調査手法・製品定義

第2章 業界概要

  • 多発性骨髄腫治療薬市場の安定した成長
  • 多発性骨髄腫:血液癌の第2位
  • 米国が最大市場でありつづけている

第3章 多発性骨髄腫治療薬市場:概要

  • 骨髄腫治療薬の支配
  • Revlimidが他の主要薬剤を凌ぐ
  • Velcade:生存率では最も優れている
  • 皮下注入
  • アンメットニーズが治療分野における更なる技術革新を促進
  • 準備中の有望薬剤があるも潜在的市場は不確実
  • Revlimid:Celgeneの主な収益源
  • Doxilが売上回復
  • 治療法
  • リスク適応療法
  • 新世代薬剤

第4章 多発性骨髄腫に関する治験

第5章 血液癌:概要と治療法

  • 血液癌治療薬:概要
  • 治療計画:黄金律
    • 臨床上の課題
    • FDAの対抗手段

第6章 疾患と治療概要

  • 癌:定義
  • 血液癌
  • 血液癌の種類
  • 血液癌の治療法

第7章 薬剤承認・上市

第8章 近年の業界活動

第9章 主要企業

  • Amgen, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • Janssen Biotech, Inc.
  • Millennium Pharmaceuticals
  • Seattle Genetics
  • Ziopharm Oncology, Inc.

第10章 世界市場見通し

第11章 米国市場

第12章 日本市場

第13章 欧州市場

第14章 その他の諸国

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: MCP-1857

This report analyzes the worldwide markets for Multiple Myeloma Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. A six-year historic analysis is also provided for these markets. The report profiles 75 companies including many key and niche players such as Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd, Genentech, Inc., Janssen Biotech, Inc., Millennium Pharmaceuticals, Seattle Genetics, and Ziopharm Oncology, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Table of Contents

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
  • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

2. INDUSTRY OVERVIEW

  • Robust Growth Ahead for Myeloma Therapeutics Market
  • Multiple Myeloma: A Second Most Common Hematological Cancer
    • Table 1: Global Multiple Myeloma Disease Statistics: 2010 (includes corresponding Graph/Chart)
    • Table 2: Global Multiple Myeloma Patient Population in Thousands under Treatment by Treatment Stage: 2010 (includes corresponding Graph/Chart)
    • Table 3: Leading Companies in the Global Oncology Therapy Market (2010): Percentage Market Share Breakdown of Revenues for Roche, Novartis, Amgen, AstraZeneca, sanofi-aventis, Celgene, and Others (includes corresponding Graph/Chart)
  • US Remains the Largest Market; Rest of World to Spearhead Growth

3. MULTIPLE MYELOMA DRUGS MARKET - AN OVERVIEW

  • The Myeloma Drug Domain
    • Table 4: Annual Revenues of Select Multiple Myeloma Drugs Worldwide: 2008 & 2009 (In US$ Million) (includes corresponding Graph/Chart)
  • Revlimid Outshines Other Leading Drugs
  • Velcade - Still the Most Superior in terms of Survival Rate
    • Table 5: Sales of Velcade in the US and Rest of World: 2008 & 2009 (In US$ Million) (includes corresponding Graph/Chart)
  • Subcutaneous Infusion - A Refuge for Velcade from Nueropathy?
  • Unmet Needs Drive Further Innovation in the Therapeutic Area
  • Promising Drugs on the Anvil, Potential Market Remains Uncertain
  • Revlimid - A Key Revenue Generator for Celgene
    • Table 6: Sales of Revlimid in the US and Rest of World: 2009 & 2010 (In US$ Million) (includes corresponding Graph/Chart)
    • Table 7: Sales of Thalomid in the US and Rest of World: 2009 & 2010 (In US$ Million) (includes corresponding Graph/Chart)
  • Doxil Regains Sales Momentum
  • Treatment Therapies: Move Up the Learning Curve
  • Risk-Adapted Therapy: The New Norm of Future Treatment
  • New Generation Drugs in the Arsenal Against Multiple Myeloma
  • Revlimid(r) (lenalidomide)
  • Velcade(r) (bortezomib)
  • Thalomid(r) (thalidomide)
  • Doxil (liposomal doxorubicin)
  • Alkeran (melphalan)
  • Trisenox(r) (arsenic trioxide)
  • Select Promising Pipeline Drugs
  • Carfilzomib (Onyx Pharmaceuticals)
    • Phase II Results of Carfilzomib
  • Pomalidomide (Celgene)
  • Noteworthy Issues Related to Major Drugs: An Evaluation of Pros and Cons
  • Revlimid Overtakes Thalomid: Why?
  • How Effective Will Thalomid Be in the 3rd Line Setting? Skepticism Overflows...
  • Revlimid Impedes Stem Cell Harvesting!!: What's the Truth?
  • Other Trends & Issues
    • Approval of New Generation Drugs Push the Market Into the Bulge Bracket
    • Growth Fundamentals Get Stronger
    • Multidrug Resistance: A Challenge to Reckon With
    • Gene Therapy Exudes Hope

4. CLINICAL TRIALS FOR MULTIPLE MYELOMA

  • Focus on Select Mid- and Late-Stage Clinical Trials in Multiple Myeloma
  • Lenalidomide versus Placebo Maintenance Treatment post Single AHSCT for Myeloma
  • Lenalidomide Maintenance Therapy Post Stem Cell Transplantation for Myeloma
  • Doxorubicin + Bortezomib + Dexamethasone versus VAD Ensued by High-Dose Melphalan and Maintenance with Thalidomide/Bortezomib in Newly Diagnosed MM Patients....
  • Weekly Bortezomib Maintenance Therapy Following Bortezomib-based Induction Therapy in Recently Diagnosed, Aged MM Sufferers...........
  • Lenalidomide in Combination with Prednisone and Melphalan in Recently Diagnosed Patients Above 65 years of Age..........
  • Bortezomib + Prednisone + Melphalan, and Thalidomide Ensued by Thalidomide + Bortezomib Maintenance for Preliminary Treatment of Aged MM Patients
  • Lenalidomide + Dexamethasone + Carfilzomib in Recently Diagnosed Multiple Myeloma
  • Carfilzomib in Refractory and Relapsed MM Setting
  • Carfilzomib as Standalone Therapy in Relapsed or Refractory MM
  • Combination of Vorinostat and Lenalidomide + Bortezomib in Relapsed/Refractory Multiple Myeloma
  • Carfilzomib in Refractory/Relapsed MM Patients (for Long-Term Tolerability and Treatment)
  • Multiple Myeloma Drugs In Pipeline in the Us As of the Year 2008
  • Phase III Drugs in Pipeline
  • Phase II Drugs in Pipeline
  • Phase I Drugs in Pipeline

5. HEMATOLOGICAL CANCERS - AN OVERVIEW & THERAPIES

  • Hematological Cancer Therapies: A Prelude
  • Treatment Regimes: The Golden Rule
    • Challenges Encountered in Clinical Trials
    • FDA's Antidotes

6. DISEASE & TREATMENT OVERVIEW

  • Cancer: A Definition
  • Hematological Cancers
  • Types of Hematological Cancer
    • Multiple Myeloma
      • Multiple Myeloma Stages
      • Stage I
      • Stage II/III
      • Treatment Procedures
      • Diagnosis
      • Treatment
      • Initial Treatment Regimen
      • Induction Therapy for SCT Candidates
      • Induction Therapy for Non-SCT Candidates
      • Therapy for Relapsed or Refractory Myeloma
      • Maintenance Therapy for Relapsed or Refractory Myeloma
      • Treatment Pros & Cons
    • Other Types of Hematological Cancers
      • Leukemia
      • Acute Lymphocytic Leukemia
      • Chronic Lymphocytic Leukemia
      • Acute Myeloid Leukemia
      • Chronic Myeloid Leukemia
      • Lymphoma
      • Non-Hodgkin's Lymphoma
      • Hodgkin's Lymphoma
      • Myelodysplastic Syndromes
  • Hematological Cancer Therapies
  • Chemotherapy
  • Radiation Therapy
  • Stem Cell Transplants
  • Biological Therapy
  • Targeted Therapy
  • Gene Therapy
  • Immunotherapy
  • Monoclonal Antibody Treatment
  • Vaccines
  • Donor Lymphocyte Infusion
  • Hematological Cancer Drug Classes
  • Hypomethylating Agents & Antimetabolites
  • Bisphosphonates
  • Alkylating Agents and DNA-Damaging Agents
  • DNA-Repair Enzyme Inhibitors
  • Histone Deacetylase Inhibitor
  • Immunomodulators
  • Proteasome Inhibitor
  • Tyrosine Kinase Inhibitors

7. DRUG APPROVALS/LAUNCHES

  • Celgene Launches Revlimid and Lenadex Drugs in Japan
  • Millennium Receives FDA Approval for Supplemental NDA of VELCADE
  • Intas Introduces Bortezomib Injection for Treating Multiple Myeloma in India
  • NICE Grants Approval for Use of Revlimid(r)
  • SWOG Announces Closure of Phase III Trial (S0232) for Paitents with Multiple Myeloma
  • Fujimoto Pharmaceutical Receives Approval to Market Thalidomide
  • Celgene Obtains Health Canada Approval for Revlimid Oral Cancer Drug
  • FDA Grants Orphan-Drug Designation to Melphalan
  • Merck Commences Phase II-b and Phase III Clinical Trial of Zolinza
  • Clavis Initiates Phase II Trial of Elacytarabine
  • Gilead Sciences Commences GS 9219 Phase I Clinical Trial
  • AstraZeneca Carries Out AZD 0530 Phase II trial
  • European Commission Grants Approval of Thalidomide for Multiple Myeloma
  • EMEA Issues Positive Opinion for Thalidomide Use in Multiple Myeloma
  • Global Regulatory Developments for the Use of Revlimid(r) in Multiple Myeloma
  • Takeda Gains FDA Approval to Promote Velcade
  • Health Canada Approves VELCADE
  • Genzyme Receives FDA Certification for Mozobil
  • Celgene's Thalidomide Pharmion Receives Marketing Authorization
  • Ziopharm Commences Phase II Clinical Trial of ZIO-101
  • FDA Approves Pluristem's Pre-IND Application of PLX-I
  • Merck Pharmaceuticals Commences Phase I Study for R763 Kinase Inhibitor
  • Swissmedic Approves Celgene's REVLIMID Oral Cancer Drug
  • Celgene's REVLIMID Receives EU's Marketing Authorization
  • FDA Approves Application of Piramal's IND-P276 Multiple Myeloma Drug
  • Millennium Pharmaceuticals and Johnson & Johnson Initiate Velcade(r) Phase II Trial
  • FDA to Consider the New Drug Application Filed for Use of Doxil(r) Combined with Velcade(r) in Patients with Multiple Myeloma
  • Ortho Biotech Files Application with FDA for Approval of Combination Drug DOXIL(r) and VELCADE(r)
  • Caraco's Allopurinol Receives FDA Approval
  • FDA Approves Thalomid(r) as Combination Therapy for Multiple Myeloma
  • Revlimid(r) Obtains Regulatory Approval for the Treatment of Multiple Myeloma
  • LymphoSign Inc. Announces Successful Completion of LS104 Drug's Pre-Clinical Testing
  • Seattle Genetics Commences SGN-40 Phase I Clinical Trial
  • FDA Approves Use of Revlimid(r) for Multiple Myeloma
  • US FDA Approves Use of Thalidomide for Multiple Myeloma
  • Ziopharm Oncology Receives Approval to Commence ZIO-101 and ZIO-201 Trial
  • FDA Grants Approval for Use of VELCADE(r) for Patients with Mantle Cell Lymphoma

8. RECENT INDUSTRY ACTIVITY

  • Onyx Files NDA for Carfilzomib in Myeloma Treatment
  • XTL Gains Orphan Drug Designation for rHuEPO
  • Signal Genetics Enters into a Commercialization Agreement with NeoGenomics Laboratories
  • The Leukemia & Lymphoma Society Forms Alliance with Acetylon Pharmaceuticals
  • Onyx Pharmaceuticals Gains FDA Fast Track Designation for Carfilzomib
  • MMRF Enters into Collaboration with Astellas Pharma
  • Takeda and Millennium Submit Two sNDA to FDA for Bortezomib
  • Astex Enters into Definitive Merger Agreement with SuperGen
  • Yakult Honsha Enters into an Agreement with Aeterna Zentaris
  • Celgene Submits MAA for REVLIMID in Europe
  • BMS Halts Tanespimycin Development
  • Acetylon Releases Pre-Clinical Data for ACY-1215 in Multiple Myeloma
  • Intellikine and MMRC Initiate Phase I Clinical Trial of INK128
  • Celgene Gains MHLW Approval for REVLIMID in Japan
  • XTL Acquires Bio-Gal
  • Compugen Discovers New Drug Target for Treating Multiple Myeloma
  • Boehringer Ingelheim Enters into a Collaboration Agreement with Micromet
  • Abbott Acquires Facet Biotech
  • Mannkind Enters Into a Research Agreement with MMRF
  • Genentech Terminates Collaboration Agreement with Seattle for SGN-40
  • Keryx Gains Fast Track Designation for Perifosine from FDA
  • FDA Clears Perifosine for Phase III Clinical Trials in Multiple Myeloma
  • CyDex Receives FDA Approval for Clinical Evaluation of CDX-353
  • Onyx Acquires Proteolix
  • Johnson & Johnson to Acquire Cougar
  • Janssen and Takeda Ink Co-Promotion Agreement
  • Eisai Establishes Subsidiary in Canada
  • Roche Group and ImmunoCellular Therapeutics Ink Licensing Agreement
  • CytRx Acquires Innovive
  • Launch of Epoetin alfa Hexal
  • PDL and Bristol-Myers Signs Agreement
  • MNKD and LLS Conclude Joint Research Agreement
  • MorphoSys and DSM Enter into Agreement
  • StemCyte Enters into Joint Venture with Cadila and Apollo Hospitals in India
  • ImmunoCellular Acquires Molecular Antibody Technology
  • US House of Representatives Sanction the Hematological Cancer Research Investment and Education Act
  • Bayer and Cell Therapeutics Enter into Mutual Agreement
  • Bristol-Myers Takes Over Kosan Biosciences
  • Bristol and PDL BioPharma Enter into Agreement
  • Gamida Cell Enters Into a Agreement with Amgen
  • Circadian Acquires Complete Stake in Vegenics
  • Takeda Acquires Millennium Pharmaceuticals
  • Access Pharmaceuticals Acquires Somanta
  • Celgene Acquires Pharmion
  • GlaxoSmithKline Forms Alliance with OncoMed for Developing Cancer Therapeutics
  • Cyclacel Acquires ALIGN Pharmaceuticals
  • Biogen and Genentech to Jointly Develop and Commercialize New Blood Cancer Drug
  • Aegera Therapeutics Acquires LymphoSign Inc
  • Velcade Gains Subsidy
  • Inex Pharmaceuticals Spins Off Biotechnology Business into Tekmira Pharmaceuticals
  • MilleGen Enters into Collaboration with LFB
  • TopoTarget Acquires Apoxis SA
  • Genentech Inks Exclusive Global Licensing Agreement with Seattle Genetics
  • PerkinElmer Takes Over ViaCell
  • Favrille Announces Acquisition of Monoclonal Antibody Range from Diversa
  • Johnson & Johnson Secures Contract worth US$112 Million
  • Bioniche Pharma Acquires Branded Pharmaceutical from Nabi Biopharmaceuticals
  • Takara Bio's RetroNect Used for Clinical Trials of Gene Therapy in Australia
  • MDS Pharma Services Becomes Recommended CRO for Multiple Myeloma Drug R&D
  • Celgene Certifies McKesson Specialty to Launch Revlimid
  • Medarex and PacMab to Co-Develop Blood Cancer Therapies
  • Gamida Cell and Teva to Co-Develop Therapy for Hematological Malignancies
  • GlaxoSmithKline Takes Over Praecis Pharmaceuticals
  • Biotest Acquires ImmunoGen Anticancer Technology Rights
  • Hana Signs Licensing Agreement with Inex
  • Cephalon Acquires Zeneus

9. FOCUS ON SELECT PLAYERS

  • Amgen, Inc. (USA)
  • Bristol-Myers Squibb Company (USA)
  • Celgene Corporation (USA)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Genentech, Inc. (USA)
  • Janssen Biotech, Inc. (USA)
  • Millennium Pharmaceuticals (USA)
  • Seattle Genetics (USA)
  • Ziopharm Oncology, Inc. (USA)

10. GLOBAL MARKET PERSPECTIVE

  • Table 8: World Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
  • Table 9: World Historic Review for Multiple Myeloma Therapeutics by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ million for Years 2003 through 2008 (includes corresponding Graph/Chart)
  • Table 10: World 15-Year Perspective for Multiple Myeloma Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

11. THE UNITED STATES

  • A. Market Analysis
    • Current & Future Analysis
      • US Myeloma Statistics
    • Table 11: Multiple Myeloma Disease Statistics in the US: 2010 (includes corresponding Graph/Chart)
    • Table 12: Addressable Multiple Myeloma Patient Population in the US by Treatment Stage: 2010 (includes corresponding Graph/Chart)
    • Table 13: Hematological Malignancies in the US (2009): Number of Incidences by Type of Cancer - Lymphoma (Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma), Multiple Myeloma, Leukemia (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, and Other Leukemia) (includes corresponding Graph/Chart)
    • Table 14: Hematological Malignancies in the US (2009): Number of Deaths by Type of Cancer - Lymphoma (Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma), Multiple Myeloma, Leukemia (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, and Other Leukemia) (includes corresponding Graph/Chart)
    • Table 15: Blood Cancer Statistics in the US (2010): Percentage Breakdown of Hematological Cancer Cases by Type: Lymphoma, Myeloma, and Leukemia (includes corresponding Graph/Chart)
    • Trends in Myeloma Therapeutics in the US
      • Doctors Shift to Continuous Therapy in Myeloma Treatment
    • Table 16: Key Drug Regimens in the US Multiple Myeloma Market (2006): Breakdown of Typical Length of Treatment Cycle and Cost per Cycle (In US$) (includes corresponding Graph/Chart)
    • Market Share Statistics
    • Table 17: Market Share Breakdown of Major Multiple Myeloma Drug Regimens in the US in First Line Setting by Number of Patients on Treatment: 2010 (includes corresponding Graph/Chart)
    • Table 18: Market Share Breakdown of Major Multiple Myeloma Drug Regimens in the US in Relapsed/ Refractory Setting by Number of Patients on Treatment: 2010 (includes corresponding Graph/Chart)
    • Table 19: US Market for Multiple Myeloma Therapeutics (2010): Percentage Market Share Breakdown of Revenues by Company - Celgene Corporation, Millennium Pharmaceuticals and Others (includes corresponding Graph/Chart)
    • Key Non-Profit Organizations in the US
      • Multiple Myeloma Research Foundation (MMRF)
      • National Coalition for Cancer Survivorship (NCCS)
      • National Marrow Donor Program (NMDP)
      • Oregon Health and Science University Cancer Institute
    • Drug Approvals
    • Strategic Corporate Developments
    • Focus on Select Key Players
  • B. Market Analytics
    • Table 20: The US Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 21: US Historic Review for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

12. JAPAN

  • A. Market Analysis
    • Current & Future Analysis
    • Myeloma in Japan
    • Table 22: Multiple Myeloma Disease Statistics in Japan: 2010 (includes corresponding Graph/Chart)
    • Table 23: Addressable Multiple Myeloma Patient Population in Japan by Treatment Stage: 2010 (includes corresponding Graph/Chart)
    • Drug Launches
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 24: Japanese Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 25: Japanese Historic Review for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

13. EUROPE

  • A. Market Analysis
    • Current & Future Analysis
    • Myeloma in the EU - A Statistical Review
    • Table 26: Multiple Myeloma Disease Statistics in the EU: 2010 (includes corresponding Graph/Chart)
    • Table 27: Addressable Multiple Myeloma Patient Population in the EU by Treatment Stage: 2010 (includes corresponding Graph/Chart)
    • Table 28: Market Share Breakdown of Major Multiple Myeloma Drug Regimens in the EU in First Line Setting by Number of Patients on Treatment: 2010 (includes corresponding Graph/Chart)
    • Table 29: Market Share Breakdown of Major Multiple Myeloma Drug Regimens in the EU in Relapsed/ Refractory Setting by Number of Patients on Treatment: 2010 (includes corresponding Graph/Chart)
    • Europe Lagging Behind in Drug Approvals
    • Thalidomide Takes Rebirth in the UK NHS
    • Strategic Corporate Developments
    • F. Hoffmann-La Roche Ltd (Switzerland) - A Key Player
  • B. Market Analytics
    • Table 30: European Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 31: European Historic Review for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

14. REST OF WORLD

  • A. Market Analysis
    • Current & Future Analysis
    • Strategic Corporate Developments
    • Drug Launch
  • B. Market Analytics
    • Table 32: Rest of World Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 33: Rest of World Historic Review for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE

Back to Top